We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04514562
Recruitment Status : Active, not recruiting
First Posted : August 17, 2020
Last Update Posted : January 17, 2023
Information provided by (Responsible Party):

Brief Summary:
A prospective, open label, single-arm 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.

Condition or disease Intervention/treatment Phase
Acute Ischemic Stroke Device: NeVa Stent Retrievers Not Applicable

Detailed Description:
This is a prospective, open label, multi-center, single-arm trial designed to assess the safety, performance and efficacy of the NeVa stent retriever in the treatment of large vessel occlusion strokes. Up to 120 eligible subjects at up 20 sites will participate in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Open-Label, Multi-Center Single-Arm Trial Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes
Actual Study Start Date : April 3, 2021
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ischemic Stroke

Arm Intervention/treatment
NeVa Stent Retrievers
Device: NeVa Stent Retrievers
mechanical neurothrombectomy

Primary Outcome Measures :
  1. Recanalization rate of the occluded target vessel [ Time Frame: During the procedure/surgery ]
    Recanalization rate of the occluded target vessel (defined by an eTICI score ≥ 2b) following three or less passes using the NeVa device(s).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke, and subject belongs to one of the following subgroups:

    1.1. Subject has failed IV t-PA therapy

    1.2. Subject is contraindicated for IV t-PA administration

    1.3. IV-tPA given within 3 hours of symptom onset

  2. Age ≥18 and ≤ 85
  3. NIHSS score ≥ 8 and ≤ 25
  4. Prestroke mRS score of ≤ 1
  5. Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA.
  6. Thrombectomy procedure can be initiated within 8 hours from symptom onset (defined as time last known well [TLKW]) and at least one NeVa pass occurring within 8 hours
  7. Imaging Inclusion Criteria:

    7.1. Non-Contrast CT Selection (if CT Perfusion or MRI not utilized): ASPECTS 6-10 , or

    7.2. CT Perfusion core ≤50 cc, or

    7.3. MRI DWI core ≤50 cc

  8. Subject or legal representative is able and willing to give informed consent prior to the intervention

Exclusion Criteria:

  1. Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
  2. Cardiopulmonary resuscitation, cardiac arrhythmia resulting in hemodynamic instability (hypotension) that is not easily medically correctable, evidence of ongoing myocardial infarction, concern for pre-treatment pulmonary aspiration.
  3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
  4. Cerebral vasculitis
  5. History of severe allergy to contrast medium.
  6. Known allergy to NeVa materials (nitinol, stainless steel);
  7. Suspicion of aortic dissection, septic embolus, or bacterial endocarditis
  8. Systemic infection
  9. Significant mass effect with midline shift
  10. Evidence of intracranial tumor (except small meningioma [≤ 3 cm])
  11. Any CT or MRI evidence of acute hemorrhage products on presentation.
  12. Inability to deploy NeVa device for at least one pass for any other reason
  13. Life expectancy less than 6 months
  14. Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
  15. Females you are pregnant or breastfeeding.
  16. Active malignancy
  17. Stenosis or occlusion in a proximal vessel requiring treatment or preventing access to the thrombus.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04514562

Layout table for location information
United States, California
Vascular Neurology of Southern California
Thousand Oaks, California, United States, 91360
United States, Florida
Baptist Health Research Institute
Jacksonville, Florida, United States, 32207
United States, Georgia
WellStar System Inc
Marietta, Georgia, United States, 30060
United States, Indiana
Community Hospital
Munster, Indiana, United States, 46321
United States, Maryland
University of Maryland Medical Center Dept of Diagnostic Radiology & Nuclear Med.
Baltimore, Maryland, United States, 21201
United States, Tennessee
Fort Sanders Regional
Knoxville, Tennessee, United States, 37902
United States, Texas
Texas Tech University Health
El Paso, Texas, United States, 79905
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Vesalio
ClinicalTrials.gov Identifier: NCT04514562    
Other Study ID Numbers: VS-001
First Posted: August 17, 2020    Key Record Dates
Last Update Posted: January 17, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Vesalio:
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemic Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases